Showing results (151-160 of 162) with videos related to

Sort By:
Pageof 17
Journal of the American College of Surgeons|October 1, 1995
Phase I-II randomized study on prehepatectomy recombinant interleukin-2 immunotherapy in patients with metastatic carcinoma of the colon and rectumD Elias, F Farace, F Triebel, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|March 27, 1999
Treatment of chronic myelogenous leukemia with interleukin-2: a phase II study in 21 patientsN Vey, D Blaise, M Lafage, et al.
International Journal of Immunopathology and Pharmacology|March 30, 2006
Soluble CD30 and lymphocyte activation gene-3 (CD223), as potential serological markers of T helper-type cytokine response induced by acellular pertussis vaccineC M Ausiello, R Palazzo, F Spensieri, et al.
Clinical and Experimental Immunology|March 1, 2011
Antibody-mediated depletion of lymphocyte-activation gene-3 (LAG-3(+) )-activated T lymphocytes prevents delayed-type hypersensitivity in non-human primatesN Poirier, T Haudebourg, C Brignone, et al.
International Journal of Cancer|May 16, 1997
MHC-dependent cytolysis of autologous tumor cells by lymphocytes infiltrating urothelial carcinomasF Housseau, D Zeliszewski, M Roy, et al.
European Cytokine Network|March 8, 2000
Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remissionD Blaise, M Attal, J Reiffers, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|July 27, 1999
Human renal cell carcinoma xenografts in SCID mice: tumorigenicity correlates with a poor clinical prognosisE Angevin, L Glukhova, C Pavon, et al.
Leukemia & Lymphoma|May 1, 1997
The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remissionD Blaise, M Attal, J L Pico, et al.
Leukemia & Lymphoma|December 30, 1998
A phase II study of interleukin-2 in 49 patients with relapsed or refractory acute leukemiaD Maraninchi, N Vey, P Viens, et al.
ESMO Open|September 24, 2023
A soluble LAG-3 protein (eftilagimod alpha) and an anti-PD-L1 antibody (avelumab) tested in a phase I trial: a new combination in immuno-oncologyS-E Al-Batran, D W Mueller, M-R Rafiyan, et al.
Pageof 17